CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-01 | Sandercock Brett Chief Financial Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −1,966 | 8,917 | ||
| 2025-07-01 | Sandercock Brett Chief Financial Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −917 | 8,000 | ||
| 2025-07-01 | Rider Michael J Global General Counsel | Sale 10b5-1 | −66 | $256.99 | $17K | 8,536 |
| 2025-06-09 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,512 |
| 2025-06-09 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $251.21 | $2.0M | 455,503 |
| 2025-06-09 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 40,047 | ||
| 2025-06-04 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $247.32 | $495K | 69,218 |
| 2025-06-02 | Rider Michael J Global General Counsel | Sale 10b5-1 | −41 | $243.78 | $10K | 8,870 |
| 2025-06-02 | Rider Michael J Global General Counsel | Shares withheld for taxes 10b5-1 | −267.24 | $244.79 | $65K | 8,603 |
| 2025-06-02 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $243.78 | $244K | 85,283 |
| 2025-05-22 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −3,644 | $244.59 | $891K | 86,283 |
| 2025-05-20 | De Witte Jan Director | Sale 10b5-1 | −2,000 | $243.47 | $487K | 5,806 |
| 2025-05-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,512 |
| 2025-05-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $243.23 | $1.9M | 455,503 |
| 2025-05-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 48,056 | ||
| 2025-05-07 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $242.25 | $485K | 71,218 |
| 2025-04-08 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $215.58 | $216K | 89,864 |
| 2025-04-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,482 |
| 2025-04-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $209.85 | $1.7M | 455,472 |
| 2025-04-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 56,065 |
Page 8 of 18 · 360 trades